STAR aims to be ‘gold standard’ for outcome measures in Sjögren’s syndrome

The Sjögren’s Tool for Assessing Response, or STAR, a candidate composite efficacy endpoint for clinical trials, includes all disease features and has demonstrated sensitivity to change, according to researchers.
“For decades, evidence-based therapy in primary Sjögren’s syndrome (pSS) has largely been based on sicca features or patient-reported outcomes (PROs),” Raphaele Seror, MD, PhD, of the Paris-Saclay University Center for Immunology of Viral Infections and Autoimmune Diseases, in France, and colleagues wrote in the Annals of the Rheumatic Diseases. “STAR

The Sjögren’s Tool for Assessing Response, or STAR, a candidate composite efficacy endpoint for clinical trials, includes all disease features and has demonstrated sensitivity to change, according to researchers.
“For decades, evidence-based therapy in primary Sjögren’s syndrome (pSS) has largely been based on sicca features or patient-reported outcomes (PROs),” Raphaele Seror, MD, PhD, of the Paris-Saclay University Center for Immunology of Viral Infections and Autoimmune Diseases, in France, and colleagues wrote in the Annals of the Rheumatic Diseases. “STAR